Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022
Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced that it will release its second-quarter financial results on August 8, 2022, after market close. A conference call for investors will take place at 5:00 p.m. ET to discuss these results. Investors can register for the call online and access a webcast on the company’s investor relations website. Akoya specializes in spatial phenotyping, providing advanced single-cell imaging solutions to enhance research in biology and health.
Positive
- Scheduled release of second-quarter financial results may indicate ongoing business operations.
- Host a conference call which shows transparency and engagement with investors.
Negative
- None.
News Market Reaction – AKYA
In the trading session that priced this news, AKYA gained 4.34%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com
Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com
